CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- 4 Open-market sale Chief Business Officer sold 10,058 shares at an average $17.73 ($178,376)
- 4 Open-market sale Chief Legal Officer sold 10,177 shares at an average $17.71 ($180,190)
- 4 Open-market buy Director bought 56,000 shares at $14.00 ($784,000)
- 4 Open-market buy Chief Scientific Officer bought 400 shares at $14.00 ($5,600)
- 4/A Open-market buy 10% owner bought 161,000 shares at $14.00 ($2,254,000)
- 4 Open-market buy Director bought 161,000 shares at $14.00 ($2,254,000)
- 4 Open-market buy Director bought 161,000 shares at $14.00 ($2,254,000)
- 3/A Insider 3/A
- 3/A Insider 3/A
- 4/A Open-market buy 10% owner bought 800,150 shares at $14.00 ($11,202,100)
- 4 Grant or award Director acquired 70,000 shares (grant or award)
- 4 Grant or award 10% owner acquired 161,000 shares (grant or award)
- 4 Open-market buy Director bought 66,500 shares at $14.00 ($931,000)
- 4 Open-market buy 10% owner bought 66,500 shares at $14.00 ($931,000)
- 4 Open-market buy 10% owner bought 800,150 shares at $14.00 ($11,202,100)
- 4 Conversion 10% owner acquired 744,380 shares (conversion)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 24 of 26 · 502 filings